ESMO 2021 | Efficacy of sacituzumab govitecan by Trop-2 expression in patients with mUC

Sacituzumab govitecan, a trop-2 targeting antibody-drug conjugate is approved by the FDA for the treatment of metastatic urothelial carcinoma (mUC), based on results from the TROPHY U-01 trial (NCT03547973). In this interview, Yohann Loriot, MD, PhD, Gustave Roussy Institute, Villejuif, France, presents the findings of an exploratory analysis evaluating the efficacy of sacituzumab govitecan by Trop-2 expression in patients with mUC. Findings suggest that high/medium Trop-2 expression is prevalent in UC and activity of sacituzumab govitecan was observed across Trop-2 expression levels. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.